To evaluate the efficacy and safety of preservative-free triamcinolone acetonide injectable suspension (Taioftal) for the treatment of macular edema secondary to diabetes or retinal vein occlusion.

Design, Setting & Participants:

From January 2015 to December 2015, at Ospedale Maggiore of Bologna, a retrospective study was conducted on patients suffering from macular edema secondary to diabetes or retinal vein occlusion. Fifty (50) eyes from fifty patients were included in this study. Only who received at least one intravitreal injection of Taioftal and followed-up at least for six months was recruited.

Main Outcome Measures:

Data were collected at baseline, week 1, month 1, month 3, and month 6 after the start of treatment. We measured best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP), and we recorded adverse events (AEs). The primary efficacy measurement was the percentage of patients who gained more than ten letters by 6-month follow-up. Other efficacy measurements were changes in BCVA, changes in CMT, and the number of retreatments. The primary safety evaluation was the percentage of patients with IOP elevation and fluctuations during six months of follow-up. Other safety evaluation was the observation of AEs, such as conjunctival haemorrhage, eye pain, conjunctivitis, endophthalmitis, retinal detachment.


Best-corrected visual acuity improved at follow-up time points compared to baseline (P≤0.01), with significantly mean gain at month 1. Central macular thickness significantly decreased compared to baseline (P≤0.001) for up to four months. IOP elevation was the most common among spotted adverse events. Nor endophthalmitis neither severe ocular complications were observed during six months of follow-up.


Intravitreal injection of Taioftal is effective at reducing central macular thickness and improving visual acuity in eyes with macular oedema secondary to diabetes or retinal vein occlusion. Temporary elevation of intraocular pressure has been manageable with topic and/or systemic medications. No serious vision-threatening complications occurred during the follow-up time.

Contact Details:

Email: manlio.nicoletti@ausl.bologna.it